Focus on Diabetes Care

Back to articles

New Insulins: The Long and Short of It

KEY POINT

The marketing of a new long-acting insulin as well as a new short-acting analogue adds versatility to products available for treating insulin-dependent patients with type 1 or 2 diabetes. Insulin glargine (Lantus—Aventis) and insulin aspart (NovoLog—Novo Nordisk) both have special capabilities that merit your attention.

SOURCES

Bolli GB, Owens DR. Insulin glargine [commentary]. Lancet. 2000;356:443–5.

Yki-Jarvinen H et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130–6.

Rosenstock J et al. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care. 2000;23:1137–42.